These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 16113602

  • 1. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
    Cohen S, Haimovich J, Hollander N.
    J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602
    [Abstract] [Full Text] [Related]

  • 2. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q.
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [Abstract] [Full Text] [Related]

  • 3. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM, Levy R.
    J Immunol; 2000 May 01; 164(9):4797-803. PubMed ID: 10779787
    [Abstract] [Full Text] [Related]

  • 4. Determination of idiotype-specific T cells in idiotype-vaccinated mice.
    Heyfets A, Haimovich J, Hollander N.
    Immunol Lett; 2002 Mar 01; 80(3):207-13. PubMed ID: 11803054
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.
    Blood; 2002 Mar 01; 99(5):1517-26. PubMed ID: 11861263
    [Abstract] [Full Text] [Related]

  • 7. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E, Okada CY.
    J Immunol; 2002 Nov 01; 169(9):5227-35. PubMed ID: 12391241
    [Abstract] [Full Text] [Related]

  • 8. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
    Lim SH, Bailey-Wood R.
    Int J Cancer; 1999 Oct 08; 83(2):215-22. PubMed ID: 10471530
    [Abstract] [Full Text] [Related]

  • 9. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P.
    Haematologica; 2003 Oct 08; 88(10):1139-49. PubMed ID: 14555310
    [Abstract] [Full Text] [Related]

  • 10. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
    Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S.
    J Immunother; 2011 Jan 08; 34(1):100-6. PubMed ID: 21150718
    [Abstract] [Full Text] [Related]

  • 11. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
    Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H.
    Br J Haematol; 2000 Mar 08; 108(4):805-16. PubMed ID: 10792287
    [Abstract] [Full Text] [Related]

  • 12. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW, Young HA, Pennington RW, Weeks SD.
    Proc Natl Acad Sci U S A; 1996 Oct 01; 93(20):10972-7. PubMed ID: 8855293
    [Abstract] [Full Text] [Related]

  • 13. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.
    Br J Haematol; 2007 Nov 01; 139(3):415-24. PubMed ID: 17910631
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses.
    Muraro S, Bondanza A, Bellone M, Greenberg PD, Bonini C.
    Blood; 2005 May 01; 105(9):3596-604. PubMed ID: 15650058
    [Abstract] [Full Text] [Related]

  • 17. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
    Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F.
    Br J Haematol; 2010 Sep 01; 150(5):554-64. PubMed ID: 20618329
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M, Frenzke H, Schmitz N, Uharek L, Steinmann J.
    Bone Marrow Transplant; 2002 Feb 01; 29(3):213-21. PubMed ID: 11859393
    [Abstract] [Full Text] [Related]

  • 20. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
    Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM.
    J Immunol; 2008 Sep 15; 181(6):4131-40. PubMed ID: 18768870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.